The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-02-14

AUTHORS

Samuel J. P. Malkin, Davide Carvalho, Catarina Costa, Vasco Conde, Barnaby Hunt

ABSTRACT

BackgroundOral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PIONEER 2 clinical trial and in a recent network meta-analysis (NMA), respectively. The aim of the present study was to evaluate the long-term cost-effectiveness of oral semaglutide 14 mg versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes from a healthcare payer perspective in Portugal.MethodsIn two separate analyses, outcomes were projected over patients’ lifetimes using the IQVIA CORE Diabetes Model (v9.0), discounted at 4% per annum. Clinical data were sourced from the PIONEER 2 trial and the NMA for the comparisons versus empagliflozin and dulaglutide, respectively. Patients were assumed to receive initial therapies until HbA1c exceeded 7.5%, then treatment-intensified to solely basal insulin therapy. Costs were accounted from a National Healthcare Service perspective in Portugal and expressed in 2021 euros (EUR). Utilities were taken from published sources.ResultsOral semaglutide 14 mg was associated with improvements in life expectancy of 0.10 and 0.03 years, and quality-adjusted life expectancy of 0.11 and 0.03 quality-adjusted life years (QALYs), versus empagliflozin 25 mg and dulaglutide 1.5 mg, respectively. Improved clinical outcomes were due to a reduced cumulative incidence and increased time to onset of diabetes-related complications with oral semaglutide. Total costs were projected to be EUR 2548 and EUR 814 higher with oral semaglutide versus empagliflozin and dulaglutide, with higher acquisition costs partially offset by cost savings from avoidance of diabetes-related complications. Oral semaglutide 14 mg was therefore associated with incremental cost-effectiveness ratios of EUR 23,571 and EUR 23,927 per QALY gained versus empagliflozin 25 mg and dulaglutide 1.5 mg, respectively.ConclusionsBased on a willingness-to-pay threshold of EUR 30,000 per QALY gained, oral semaglutide 14 mg was considered cost-effective versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes in Portugal. More... »

PAGES

32

References to SciGraph publications

  • 2022-01-21. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting in PHARMACOECONOMICS - OPEN
  • 2017-01-09. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries in DIABETES THERAPY
  • 2013-06-03. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2019-08-24. Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review in DIABETES THERAPY
  • 2007-04-06. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration in DIABETOLOGIA
  • 2019-04-26. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data in DIABETES THERAPY
  • 2019-12-12. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme in DIABETES THERAPY
  • 2018-01-04. A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study in DIABETES THERAPY
  • 2014-05-17. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries in QUALITY OF LIFE RESEARCH
  • 2019-12-19. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in DIABETOLOGIA
  • 2019-05-16. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting in DIABETES THERAPY
  • 2019-10-10. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis in DIABETES THERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s13098-022-00801-4

    DOI

    http://dx.doi.org/10.1186/s13098-022-00801-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1145514337

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35164855


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications GmbH, B\u00e4umleingasse 20, 4051, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications GmbH, B\u00e4umleingasse 20, 4051, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Malkin", 
            "givenName": "Samuel J. P.", 
            "id": "sg:person.012067446720.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universit\u00e1rio de S Jo\u00e3o, Faculty of Medicine and Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Porto, Portugal", 
              "id": "http://www.grid.ac/institutes/grid.5808.5", 
              "name": [
                "Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universit\u00e1rio de S Jo\u00e3o, Faculty of Medicine and Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Porto, Portugal"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carvalho", 
            "givenName": "Davide", 
            "id": "sg:person.011043337005.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011043337005.69"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk Portugal, Lda, Pa\u00e7o de Arcos, Portugal", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk Portugal, Lda, Pa\u00e7o de Arcos, Portugal"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Costa", 
            "givenName": "Catarina", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novo Nordisk Portugal, Lda, Pa\u00e7o de Arcos, Portugal", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Novo Nordisk Portugal, Lda, Pa\u00e7o de Arcos, Portugal"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Conde", 
            "givenName": "Vasco", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ossian Health Economics and Communications GmbH, B\u00e4umleingasse 20, 4051, Basel, Switzerland", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Ossian Health Economics and Communications GmbH, B\u00e4umleingasse 20, 4051, Basel, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hunt", 
            "givenName": "Barnaby", 
            "id": "sg:person.01346701147.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00125-019-05039-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123509299", 
              "https://doi.org/10.1007/s00125-019-05039-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-00681-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1120524399", 
              "https://doi.org/10.1007/s13300-019-00681-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s41669-021-00317-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1144862682", 
              "https://doi.org/10.1007/s41669-021-00317-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00125-007-0599-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010943073", 
              "https://doi.org/10.1007/s00125-007-0599-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-0630-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1114500568", 
              "https://doi.org/10.1007/s13300-019-0630-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-0615-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113754031", 
              "https://doi.org/10.1007/s13300-019-0615-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-00736-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123313018", 
              "https://doi.org/10.1007/s13300-019-00736-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1477-7525-11-90", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013049175", 
              "https://doi.org/10.1186/1477-7525-11-90"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-016-0224-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006201032", 
              "https://doi.org/10.1007/s13300-016-0224-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-019-00706-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1121626574", 
              "https://doi.org/10.1007/s13300-019-00706-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11136-014-0712-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041603789", 
              "https://doi.org/10.1007/s11136-014-0712-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13300-017-0361-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100200263", 
              "https://doi.org/10.1007/s13300-017-0361-5"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-02-14", 
        "datePublishedReg": "2022-02-14", 
        "description": "BackgroundOral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PIONEER 2 clinical trial and in a recent network meta-analysis (NMA), respectively. The aim of the present study was to evaluate the long-term cost-effectiveness of oral semaglutide 14\u00a0mg versus empagliflozin 25\u00a0mg and dulaglutide 1.5\u00a0mg for the treatment of type 2 diabetes from a healthcare payer perspective in Portugal.MethodsIn two separate analyses, outcomes were projected over patients\u2019 lifetimes using the IQVIA CORE Diabetes Model (v9.0), discounted at 4% per annum. Clinical data were sourced from the PIONEER 2 trial and the NMA for the comparisons versus empagliflozin and dulaglutide, respectively. Patients were assumed to receive initial therapies until HbA1c exceeded 7.5%, then treatment-intensified to solely basal insulin therapy. Costs were accounted from a National Healthcare Service perspective in Portugal and expressed in 2021 euros (EUR). Utilities were taken from published sources.ResultsOral semaglutide 14\u00a0mg was associated with improvements in life expectancy of 0.10 and 0.03\u00a0years, and quality-adjusted life expectancy of 0.11 and 0.03 quality-adjusted life years (QALYs), versus empagliflozin 25\u00a0mg and dulaglutide 1.5\u00a0mg, respectively. Improved clinical outcomes were due to a reduced cumulative incidence and increased time to onset of diabetes-related complications with oral semaglutide. Total costs were projected to be EUR\u00a02548 and EUR\u00a0814 higher with oral semaglutide versus empagliflozin and dulaglutide, with higher acquisition costs partially offset by cost savings from avoidance of diabetes-related complications. Oral semaglutide 14\u00a0mg was therefore associated with incremental cost-effectiveness ratios of EUR 23,571 and EUR\u00a023,927 per QALY gained versus empagliflozin 25\u00a0mg and dulaglutide 1.5\u00a0mg, respectively.ConclusionsBased on a willingness-to-pay threshold of EUR\u00a030,000 per QALY gained, oral semaglutide 14\u00a0mg was considered cost-effective versus empagliflozin 25\u00a0mg and dulaglutide 1.5\u00a0mg for the treatment of type 2 diabetes in Portugal.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s13098-022-00801-4", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1040785", 
            "issn": [
              "1758-5996"
            ], 
            "name": "Diabetology & Metabolic Syndrome", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "14"
          }
        ], 
        "keywords": [
          "quality-adjusted life years", 
          "oral semaglutide 14", 
          "diabetes-related complications", 
          "empagliflozin 25", 
          "type 2 diabetes", 
          "oral semaglutide", 
          "novel glucagon-like peptide-1 (GLP-1) analogue", 
          "sodium glucose cotransporter 2 inhibitor empagliflozin", 
          "GLP-1 receptor agonist dulaglutide", 
          "glucagon-like peptide-1 analog", 
          "incremental cost-effectiveness ratio", 
          "threshold of euro", 
          "peptide-1 analog", 
          "life expectancy", 
          "healthcare payer perspective", 
          "quality-adjusted life expectancy", 
          "cost-effectiveness ratio", 
          "initial therapy", 
          "inhibitor empagliflozin", 
          "insulin therapy", 
          "cumulative incidence", 
          "clinical outcomes", 
          "higher acquisition cost", 
          "clinical trials", 
          "payer perspective", 
          "IQVIA CORE", 
          "clinical data", 
          "dulaglutide", 
          "body weight", 
          "semaglutide", 
          "empagliflozin", 
          "life years", 
          "complications", 
          "diabetes", 
          "patients", 
          "therapy", 
          "trials", 
          "present study", 
          "outcomes", 
          "treatment", 
          "separate analysis", 
          "service perspective", 
          "acquisition costs", 
          "expectancy", 
          "cost savings", 
          "years", 
          "incidence", 
          "hemoglobin", 
          "NMA", 
          "onset", 
          "total cost", 
          "recent network", 
          "improvement", 
          "aim", 
          "euro", 
          "weight", 
          "study", 
          "utility", 
          "avoidance", 
          "threshold", 
          "analogues", 
          "annum", 
          "data", 
          "willingness", 
          "ratio", 
          "time", 
          "comparison", 
          "Portugal", 
          "analysis", 
          "cost", 
          "perspective", 
          "model", 
          "source", 
          "savings", 
          "network", 
          "lifetime", 
          "core"
        ], 
        "name": "The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal", 
        "pagination": "32", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1145514337"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s13098-022-00801-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35164855"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s13098-022-00801-4", 
          "https://app.dimensions.ai/details/publication/pub.1145514337"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:44", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_951.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s13098-022-00801-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13098-022-00801-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13098-022-00801-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13098-022-00801-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13098-022-00801-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    216 TRIPLES      21 PREDICATES      114 URIs      94 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s13098-022-00801-4 schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 schema:author Ne7bf36cfb6194d9eb5447bf2add5a511
    4 schema:citation sg:pub.10.1007/s00125-007-0599-y
    5 sg:pub.10.1007/s00125-019-05039-w
    6 sg:pub.10.1007/s11136-014-0712-x
    7 sg:pub.10.1007/s13300-016-0224-5
    8 sg:pub.10.1007/s13300-017-0361-5
    9 sg:pub.10.1007/s13300-019-00681-4
    10 sg:pub.10.1007/s13300-019-00706-y
    11 sg:pub.10.1007/s13300-019-00736-6
    12 sg:pub.10.1007/s13300-019-0615-5
    13 sg:pub.10.1007/s13300-019-0630-6
    14 sg:pub.10.1007/s41669-021-00317-z
    15 sg:pub.10.1186/1477-7525-11-90
    16 schema:datePublished 2022-02-14
    17 schema:datePublishedReg 2022-02-14
    18 schema:description BackgroundOral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PIONEER 2 clinical trial and in a recent network meta-analysis (NMA), respectively. The aim of the present study was to evaluate the long-term cost-effectiveness of oral semaglutide 14 mg versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes from a healthcare payer perspective in Portugal.MethodsIn two separate analyses, outcomes were projected over patients’ lifetimes using the IQVIA CORE Diabetes Model (v9.0), discounted at 4% per annum. Clinical data were sourced from the PIONEER 2 trial and the NMA for the comparisons versus empagliflozin and dulaglutide, respectively. Patients were assumed to receive initial therapies until HbA1c exceeded 7.5%, then treatment-intensified to solely basal insulin therapy. Costs were accounted from a National Healthcare Service perspective in Portugal and expressed in 2021 euros (EUR). Utilities were taken from published sources.ResultsOral semaglutide 14 mg was associated with improvements in life expectancy of 0.10 and 0.03 years, and quality-adjusted life expectancy of 0.11 and 0.03 quality-adjusted life years (QALYs), versus empagliflozin 25 mg and dulaglutide 1.5 mg, respectively. Improved clinical outcomes were due to a reduced cumulative incidence and increased time to onset of diabetes-related complications with oral semaglutide. Total costs were projected to be EUR 2548 and EUR 814 higher with oral semaglutide versus empagliflozin and dulaglutide, with higher acquisition costs partially offset by cost savings from avoidance of diabetes-related complications. Oral semaglutide 14 mg was therefore associated with incremental cost-effectiveness ratios of EUR 23,571 and EUR 23,927 per QALY gained versus empagliflozin 25 mg and dulaglutide 1.5 mg, respectively.ConclusionsBased on a willingness-to-pay threshold of EUR 30,000 per QALY gained, oral semaglutide 14 mg was considered cost-effective versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes in Portugal.
    19 schema:genre article
    20 schema:isAccessibleForFree true
    21 schema:isPartOf N4e8e89c2220e451fbfaff0a6d4462cd9
    22 Na10adfb1cb3d433fb34d8dd1c850ba7d
    23 sg:journal.1040785
    24 schema:keywords GLP-1 receptor agonist dulaglutide
    25 IQVIA CORE
    26 NMA
    27 Portugal
    28 acquisition costs
    29 aim
    30 analogues
    31 analysis
    32 annum
    33 avoidance
    34 body weight
    35 clinical data
    36 clinical outcomes
    37 clinical trials
    38 comparison
    39 complications
    40 core
    41 cost
    42 cost savings
    43 cost-effectiveness ratio
    44 cumulative incidence
    45 data
    46 diabetes
    47 diabetes-related complications
    48 dulaglutide
    49 empagliflozin
    50 empagliflozin 25
    51 euro
    52 expectancy
    53 glucagon-like peptide-1 analog
    54 healthcare payer perspective
    55 hemoglobin
    56 higher acquisition cost
    57 improvement
    58 incidence
    59 incremental cost-effectiveness ratio
    60 inhibitor empagliflozin
    61 initial therapy
    62 insulin therapy
    63 life expectancy
    64 life years
    65 lifetime
    66 model
    67 network
    68 novel glucagon-like peptide-1 (GLP-1) analogue
    69 onset
    70 oral semaglutide
    71 oral semaglutide 14
    72 outcomes
    73 patients
    74 payer perspective
    75 peptide-1 analog
    76 perspective
    77 present study
    78 quality-adjusted life expectancy
    79 quality-adjusted life years
    80 ratio
    81 recent network
    82 savings
    83 semaglutide
    84 separate analysis
    85 service perspective
    86 sodium glucose cotransporter 2 inhibitor empagliflozin
    87 source
    88 study
    89 therapy
    90 threshold
    91 threshold of euro
    92 time
    93 total cost
    94 treatment
    95 trials
    96 type 2 diabetes
    97 utility
    98 weight
    99 willingness
    100 years
    101 schema:name The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
    102 schema:pagination 32
    103 schema:productId N1e75de86e2554bafa50ff274327f92e1
    104 Nc4c8872dd92044ef95ad2ad4ebf0e5c5
    105 Ne502d534c3e14e39b55e88d97105d66a
    106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145514337
    107 https://doi.org/10.1186/s13098-022-00801-4
    108 schema:sdDatePublished 2022-12-01T06:44
    109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    110 schema:sdPublisher Ndd087becb8ed4634b864e701fbf8ff16
    111 schema:url https://doi.org/10.1186/s13098-022-00801-4
    112 sgo:license sg:explorer/license/
    113 sgo:sdDataset articles
    114 rdf:type schema:ScholarlyArticle
    115 N13eeb9f8ff24423cb7d7ad169a383e2a rdf:first sg:person.01346701147.33
    116 rdf:rest rdf:nil
    117 N1e75de86e2554bafa50ff274327f92e1 schema:name dimensions_id
    118 schema:value pub.1145514337
    119 rdf:type schema:PropertyValue
    120 N4e8e89c2220e451fbfaff0a6d4462cd9 schema:issueNumber 1
    121 rdf:type schema:PublicationIssue
    122 N8d65aa78c54e49208b497e1043532b13 schema:affiliation grid-institutes:None
    123 schema:familyName Conde
    124 schema:givenName Vasco
    125 rdf:type schema:Person
    126 Na10adfb1cb3d433fb34d8dd1c850ba7d schema:volumeNumber 14
    127 rdf:type schema:PublicationVolume
    128 Nc2d147c56e0b432f8ca9b777fd42eec6 rdf:first N8d65aa78c54e49208b497e1043532b13
    129 rdf:rest N13eeb9f8ff24423cb7d7ad169a383e2a
    130 Nc4c8872dd92044ef95ad2ad4ebf0e5c5 schema:name pubmed_id
    131 schema:value 35164855
    132 rdf:type schema:PropertyValue
    133 Nd03a48ddaf4047eab9d8472504ea33e2 rdf:first sg:person.011043337005.69
    134 rdf:rest Nfc3329a2015141cb822e4757a57c1e89
    135 Ndafa8dfe52164d5b9f9341747e366a4e schema:affiliation grid-institutes:None
    136 schema:familyName Costa
    137 schema:givenName Catarina
    138 rdf:type schema:Person
    139 Ndd087becb8ed4634b864e701fbf8ff16 schema:name Springer Nature - SN SciGraph project
    140 rdf:type schema:Organization
    141 Ne502d534c3e14e39b55e88d97105d66a schema:name doi
    142 schema:value 10.1186/s13098-022-00801-4
    143 rdf:type schema:PropertyValue
    144 Ne7bf36cfb6194d9eb5447bf2add5a511 rdf:first sg:person.012067446720.22
    145 rdf:rest Nd03a48ddaf4047eab9d8472504ea33e2
    146 Nfc3329a2015141cb822e4757a57c1e89 rdf:first Ndafa8dfe52164d5b9f9341747e366a4e
    147 rdf:rest Nc2d147c56e0b432f8ca9b777fd42eec6
    148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    149 schema:name Medical and Health Sciences
    150 rdf:type schema:DefinedTerm
    151 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    152 schema:name Clinical Sciences
    153 rdf:type schema:DefinedTerm
    154 sg:journal.1040785 schema:issn 1758-5996
    155 schema:name Diabetology & Metabolic Syndrome
    156 schema:publisher Springer Nature
    157 rdf:type schema:Periodical
    158 sg:person.011043337005.69 schema:affiliation grid-institutes:grid.5808.5
    159 schema:familyName Carvalho
    160 schema:givenName Davide
    161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011043337005.69
    162 rdf:type schema:Person
    163 sg:person.012067446720.22 schema:affiliation grid-institutes:None
    164 schema:familyName Malkin
    165 schema:givenName Samuel J. P.
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
    167 rdf:type schema:Person
    168 sg:person.01346701147.33 schema:affiliation grid-institutes:None
    169 schema:familyName Hunt
    170 schema:givenName Barnaby
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
    172 rdf:type schema:Person
    173 sg:pub.10.1007/s00125-007-0599-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010943073
    174 https://doi.org/10.1007/s00125-007-0599-y
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1007/s00125-019-05039-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1123509299
    177 https://doi.org/10.1007/s00125-019-05039-w
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1007/s11136-014-0712-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041603789
    180 https://doi.org/10.1007/s11136-014-0712-x
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/s13300-016-0224-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006201032
    183 https://doi.org/10.1007/s13300-016-0224-5
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1007/s13300-017-0361-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100200263
    186 https://doi.org/10.1007/s13300-017-0361-5
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1007/s13300-019-00681-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120524399
    189 https://doi.org/10.1007/s13300-019-00681-4
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1007/s13300-019-00706-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1121626574
    192 https://doi.org/10.1007/s13300-019-00706-y
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1007/s13300-019-00736-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123313018
    195 https://doi.org/10.1007/s13300-019-00736-6
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1007/s13300-019-0615-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113754031
    198 https://doi.org/10.1007/s13300-019-0615-5
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1007/s13300-019-0630-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1114500568
    201 https://doi.org/10.1007/s13300-019-0630-6
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1007/s41669-021-00317-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1144862682
    204 https://doi.org/10.1007/s41669-021-00317-z
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
    207 https://doi.org/10.1186/1477-7525-11-90
    208 rdf:type schema:CreativeWork
    209 grid-institutes:None schema:alternateName Novo Nordisk Portugal, Lda, Paço de Arcos, Portugal
    210 Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland
    211 schema:name Novo Nordisk Portugal, Lda, Paço de Arcos, Portugal
    212 Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland
    213 rdf:type schema:Organization
    214 grid-institutes:grid.5808.5 schema:alternateName Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de S João, Faculty of Medicine and Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    215 schema:name Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de S João, Faculty of Medicine and Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
    216 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...